Summary & Overview
HCPCS Q9991: Buprenorphine Extended-Release (Sublocade) ≤100 mg Injection
HCPCS Level II code Q9991 denotes the injection of buprenorphine extended-release (Sublocade) at doses of 100 mg or less. This long-acting buprenorphine formulation is part of medication-assisted treatment for opioid use disorder and is administered as a subcutaneous injection in outpatient or ambulatory settings. Nationally, use of long-acting buprenorphine formulations influences access to evidence-based treatment, continuity of care, and payer coverage policy decisions.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the clinical context for extended-release buprenorphine injections, and the payer landscape typically associated with coverage and billing for injectable MAT products. The publication highlights benchmarks and policy considerations relevant to billing and reimbursement for this service, as well as clinical context about administration settings and service type.
This summary provides a national perspective on coding and coverage implications rather than state-specific guidance. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code Q9991 represents an injection of buprenorphine extended-release (Sublocade), less than or equal to 100 mg. This code covers administration of the long-acting, subcutaneous formulation of buprenorphine used for treatment of opioid use disorder.
Service Type: Medication injection / Medication-assisted treatment (MAT)
Typical Site of Service: Outpatient clinic, outpatient behavioral health setting, or ambulatory care center
Clinical & Coding Specifications
Clinical Context
A 35-year-old patient with a history of moderate to severe opioid use disorder presents to an outpatient addiction treatment clinic for a planned monthly maintenance injection of buprenorphine extended-release (Sublocade). The patient has completed induction and stabilization on transmucosal buprenorphine and met the criteria for transition to a monthly subcutaneous depot formulation. The clinical workflow includes verification of identity and consent, review of prior treatment and adherence, assessment for contraindications (active severe hepatic impairment, hypersensitivity), and documentation of recent urine drug screen. The medication is supplied by the clinic or specialty pharmacy, refrigerated per product labeling, and prepared by a licensed clinician. The clinician performs an abdominal subcutaneous injection following aseptic technique, observes the patient for a short period for immediate adverse reactions, documents lot number and dose, and schedules the next monthly visit. Billing is submitted using the HCPCS Level II code Q9991 for Sublocade 100 mg (or less), with applicable facility or professional modifiers and supporting ICD-10 diagnosis codes for opioid use disorder recorded on the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / unmodified service | Use when no specific modifier applies and standard billing is appropriate. |